Mubadala and G42 Sign Deal For a New Biopharma Manufacturing Campus in Abu Dhabi
Posted on 12/24/2021
Sovereign investor giant Mubadala Investment Company and G42 have signed an agreement to establish a new biopharmaceutical manufacturing campus (Biopharma Campus) in Abu Dhabi. The proposed facility will focus on vaccine and therapeutic products to strengthen regional supply chains and support the UAE’s diversification plan, a statement said. Abu Dhabi-based G42 develops and deploys high-impact industry solutions in sectors like the government, healthcare, finance, sports, energy, and smart cities.
The campus seeks to be an end-to-end manufacturing of biologics and host anchor partnerships with contract manufacturing and development organizations (CDMOs).